Skip to main content
SpringerLink
Log in

Costs of Mini Mental State Examination-Related Cognitive Impairment

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To investigate the relationship between cognitive impairment, measured with the Mini Mental State Examination (MMSE), and the cost of care.

Design: The study uses data from the Kungsholmen project, a population-based study in Sweden in which people 75 years and older were observed over time. The initial study population (n = 1810) was divided into 4 health states based on the MMSE. A Markov model was constructed from the transition probabilities between different states between the first and second phases of the study. The expected cost of cognitive impairment for a period of 10 years was estimated for the cohort of patients studied.

Main outcome measures and results: There was a strong correlation between cognitive impairment in terms of the MMSE and the annual cost of care. A multivariate statistical analysis showed that a decrease in the MMSE by 1 point was associated with an increase in the cost of care of 15 000 Swedish kronor (SEK) [$US2000; 1995 values].

Conclusions: The results show that large savings are possible if the decline in cognitive functioning can be prevented. The model developed can be used to estimate the impact on cost of care of treatments which reduce the cognitive decline in patients with Alzheimer’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Reisberg B, Ferris SH, Kluger A, et al. Symptomatic changes in CNS aging and dementia of the Alzheimer type: cross-sectional, temporal and remediable concomitants. In: Bergener M, Reisberg B, editors. Diagnosis and treatment of senile dementia. Berlin-Heidelberg: SpringerVerlag, 1989: 193–223

    Chapter  Google Scholar 

  2. Baines S, Saxby P, Ehlert K. Reality orientation and reminiscence therapy: a controlled cross-over study of confused people. Br J Psychiatry 1987; 151: 222–31

    Article  PubMed  CAS  Google Scholar 

  3. Wimo A, Eriksson T, Mattsson B, et al. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995; 11: 49–65

    Article  PubMed  CAS  Google Scholar 

  4. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92

    Article  PubMed  CAS  Google Scholar 

  5. Rogers SL, Freidhoff LT, the Donezepil Study Group. The efficacy and safety of donezepil in patients with Alzheimer’s Disease: results of a US multicentre, randomized, doubleblind, placebo-controlled trial. Dementia 1996; 7: 293–303

    PubMed  CAS  Google Scholar 

  6. McRae A, Rudolphi K, Schubert P. Propentofylline depresses amyloid and Alzheimer’s CSF microglial antigens after ischaemia. Neuroreport 1994; 5: 1193–6

    Article  PubMed  CAS  Google Scholar 

  7. Winblad B, Hill S, Beermann B, et al. Issues in the economic evaluation of treatment for dementia. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 3: 39–45

    PubMed  Google Scholar 

  8. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980–1990 findings. Int J Epidemiol 1991; 20: 736–48

    Article  PubMed  CAS  Google Scholar 

  9. Schneider EL, Guralnik JM. The aging of America: impact on health care costs. JAMA 1990; 263: 2335–40

    Article  PubMed  CAS  Google Scholar 

  10. Fratiglioni L, Grut M, Forsell Y, et al. Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: relationship with age, sex and education. Neurology 1991; 41: 1886–92

    Article  PubMed  CAS  Google Scholar 

  11. Corder E, Basun H, Lannfelt L, et al. Apolipoprotein E 4 gene dose. Lancet 1995; 346: 967–8

    CAS  Google Scholar 

  12. 1966 Lancet Conference Writing Committee. The challenge of dementias. Lancet 1996; 347: 1303–7

    Article  Google Scholar 

  13. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int JGeriatr Psychiatry 1997; 12: 841–56

    Article  CAS  Google Scholar 

  14. Drummond MF, Mohide EA, Tew M, et al. Economic evaluation of a support program for caregivers of demented elderly. Int J Technol Assess Health Care 1992; 7: 209–19

    Article  Google Scholar 

  15. Lubeck DP, Mazonson PD, Bowe T. The potential impact of tacrine on expenditures for Alzheimer’s disease. Med Interface 1994; 7: 130–8

    PubMed  CAS  Google Scholar 

  16. Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer’s disease with tacrine: a cost analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191–200

    PubMed  CAS  Google Scholar 

  17. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of tacrine and the measurement of outcomes in Alzheimers disease. Ottawa (ON): CCOHTA, 1997

    Google Scholar 

  18. Sonnenberg FA, Beck JR. Markov models in decision making: a practical guide. Med Decis Making 1993; 13: 322–38

    Article  PubMed  CAS  Google Scholar 

  19. Folstein MF, Folstein SE, McHugh PR. ’Mini-mental’ state: a practical method for grading the cognitive state of patients for the clinician. Psychiatry Res 1975; 12: 189–98

    Article  CAS  Google Scholar 

  20. Koopmanschap MA, Polder JJ, Meering WJ, et al. Cost of dementia in the Netherlands. In: Wimo A, Jönsson B, Karlsson G, et al., editors. Health economics of dementia. Chichester: Wiley, 1998: 207–14

    Google Scholar 

  21. Fratiglioni L, Forsell Y, Aguero Torres H, et al. Severity of dementia and institutionalization in the elderly: prevalence data from an urban area in Sweden. Neuroepidemiology 1994; 13: 79–88

    Article  PubMed  CAS  Google Scholar 

  22. Fratiglioni L, Viitanen M, von Strauss E, et al. Very old women at highest risk of dementia and Alzheimer’s disease: incidence data from the Kungsholmen project, Stockholm. Neurology 1997; 136: 132–8

    Article  Google Scholar 

  23. Statistics Sweden. Consumer price index 1914–1995: statistiska meddelanden P 15 SM 9601, 1996. Stockholm: Statistics Sweden, 1996

    Google Scholar 

  24. The Federation of County Councils in Sweden. Kostnad per intagen patient, vårddag, läkarbesök mm 1993. Stockholm: the Federation of County Councils in Sweden, 1994

    Google Scholar 

  25. Svensson M, Edebalk PG, Persson U. Group living for elderly patients with dementia: a cost analysis. Health Policy 1996; 38 (2): 83–100

    Article  PubMed  CAS  Google Scholar 

  26. The Federation of the Swedish Municipalities. Stockholm: The Federation of the Swedish Municipalities. (Data on file)

  27. Pharmaceutical Specialities in Sweden (FASS). LINFO. Stockholm: Läkemedelsinformation AB, 1996

    Google Scholar 

  28. Wimo A, Mattsson B, Krakau I, et al. The impact of different levels of cognitive decline and work load on costs of dementia care at different caring levels. Int J Geriatr Psychiatry 1994; 9: 479–89

    Article  Google Scholar 

  29. Wimo A, Mattsson B, Gustafsson L. Predictive validity of factors influencing the institutionalization of elderly people with psycho-geriatric disorders. Scand J Prim Health Care 1992; 10: 185–91

    Article  PubMed  CAS  Google Scholar 

  30. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimers disease. Arch Neurol 1997; 54: 687–93

    Article  PubMed  CAS  Google Scholar 

  31. Boada M, Hart W, Pena J, et al. Estimated health and social cost of Alzheimer’s disease in community patients in Spain. Alzheimer Disease International (ADI), Alzheimer Europe (AE) and Alözheimer Society of Finland. Alzheimer: the blind hunter: 1997 Sep 29 - Oct 1; Helsinki

  32. Schulenburg JM, Schulenburg I, Horn R, et al. Cost of treatment and care of Alzheimer’s disease in Germany. In: Wimo A, Jönsson B, Karlsson G, et al., editors. Health economics of dementia. Chichester: Wiley, 1998: 217–30

    Google Scholar 

  33. Fastbom J, Giron MST. Drug costs in dementia care. In: Wimo A, Jönsson B, Karlsson G, et al., editors. Health economics of dementia. Chichester: Wiley, 1998: 285–14

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stockholm School of Economics, Box 6501, S-113 83, Stockholm, Sweden

    Linus Jönsson, Peter Lindgren, Anders Wimo &  Bengt Jönsson

Authors
  1. Linus Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Lindgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anders Wimo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bengt Jönsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bengt Winblad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bengt Jönsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jönsson, L., Lindgren, P., Wimo, A. et al. Costs of Mini Mental State Examination-Related Cognitive Impairment. Pharmacoeconomics 16, 409–416 (1999). https://doi.org/10.2165/00019053-199916040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916040-00008

Keywords

Search

Navigation